Discovery of a potent, selective, and orally bioavailable c-met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl) -5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)

Journal of Medicinal Chemistry

Volumn 51, Issue 13, 2008, Pages 3688-3691

  Liu, Longbin ^b   Siegmund, Aaron ^b   Xi, Ning ^b   Kaplan Lefko, Paula ^b   Rex, Karen ^b   Chen, April ^b   Lin, Jasmine ^b   Moriguchi, Jodi ^b   Berry, Loren ^b   Huang, Liyue ^b   Teffera, Yohannes ^b   Yang, Yajing ^b   Zhang, Yihong ^b   Bellon, Steven F ^b   Lee, Matthew ^b   Shimanovich, Roman ^b   Bak, Annette ^b   Dominguez, Celia ^a   Norman, Mark H ^b   Harmange, Jean Christophe ^b   Dussault, Isabelle ^b   Kim, Tae Seong ^b   more..

^a CHD1 Management Inc   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXY 2 METHYLPROPYL) N [5 (7 METHOXYQUINOLIN 4 YLOXY)PYRIDIN 2 YL] 5 METHYL 3 OXO 2 PHENYL 2,3 DIHYDRO 1H PYRAZOLE 4 CARBOXAMIDE; AMG 458; ANTINEOPLASTIC AGENT; SCATTER FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; AMINOPYRIDINES; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; DRUG DESIGN; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 46849101000     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800401t     Document Type: Article

References (30)

1. (a) Bottaro, D. P.; Rubin, J. S.; Faletto, D. L.; Chan, A. M.; Kmiecik, T. E.; Vande Woude, G. F.; Aaronson, S. A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251, 802-804.
2. (b) Naldini, L.; Weidner, K. M.; Vigna, E.; Gaudino, G.; Bardelli, A.; Ponzetto, C.; Narsimhan, R. P.; Hartmann, G.; Zarnegar, R.; Michalopoulos, G. K. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 1991, 10, 2867-2878.
3. (a) Sattler, M.; Salgia, R. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr. Oncol. Rep. 2007, 9, 102-108.
4. (b) Mazzone, M.; Comoglio, P. M. The Met pathway: master switch and drug target in cancer progression. FASEB J. 2006, 20, 1611-1621.
5. (c) Trusolino, L.; Comoglio, P. M. Scatter-factor and semaphorin receptors: cell signaling for invasive growth. Nat. Rev. Cancer 2002, 2, 289-300.
6. (a) Jarvis, L. M. One pill, many uses. Chem. Eng. News 2007, 85, 15-23.
7. (b) Christensen, J.; Burrows, J.; Salgia, R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005, 225, 1-25.
8. (c) Dussault, I.; Kaplan-Lefko, P.; Jun, T.; Coxon, A.; Burgess, T. L. HGF- and c-Met-targeted drugs: hopes, challenges and their future in cancer therapy. Drugs Future 2006, 31, 819-825.
9. (d) Abidoye, O.; Murukurthy, N.; Salgia, R. Review of clinical trials: agents targeting c-Met. Rev. Recent Clin. Trials 2007, 2, 143-147.
10. (a) Sattler, M.; Pride, Y. B.; Ma, P.; Gramlich, J. L.; Chu, S. C.; Quinnan, L. A.; Shirazian, S.; Liang, C.; Podar, K.; Christensen, J. G.; Salgia, R. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003, 63, 5462-5469.
11. (b) Christensen, J. G.; Schreck, R.; Burrows., J.; Kuruganti, P.; Chan, E.; Le, P.; Chen, J.; Wang, X.; Ruslim, L.; Blake, R.; Lipson, K. E.; Ramphal, J.; Do S Cui, J. J.; Cherrington, J. M.; Mendel, D. B. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003, 63, 7345-7355.
12. Zou, H. Y.; Li, Q.; Lee. J. H.; Arango, M. E.; McDonnell, S. R.; Yamazaki, S.; Koudriakova, T. B.; Alton, G.; Cui, J. J.; Kung, P. P.; Nambu, M. D.; Los, G.; Bender, S. L.; Mroczkowski, B.; Christensen, J. G. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67, 4408-4417.
13. For a preliminary discussion on the aspect of structural based design leading to 17, see the following: Choquette, D.; Liu, L. ; Kim, T.-S.; Norman, M. H.; Siegmund, A.; Xi, N.; Bellon, S. F.; Kaplan-Lefko, P.; Lee, M.; Lin, J.; Rex, K.; Teffera, Y.; Dussault, I.; Harmange, J. C. Discovery of AMG 458: An Orally Bioavailable, Selective c-Met Inhibitor. Presented at the AACR Annual Meeting, San Diego, CA, April 12-16, 2008.
14. (a) The discovery and detailed SAR studies of 1 will be reported in a separate publication. J. Med. Chem., to be submitted.
15. (b) For the synthesis and nomenclature of the pyrazolone piece leading to 4 and 5, see ref 10 (and ref 16 therein).
16. (a) Baka, S.; Clamp, A. R.; Jayson, G. C. A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin. Ther. Targets 2006, 10, 867-876.
17. (b) Gasparini, G.; Longo, R.; Toi, M.; Ferrara, N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol. 2005, 2, 562-577.
18. Other strategies to address the issue of ketone formation such as protecting the OH group as methyl ether, or introducing alkyl groups flanking the OH group, were less successful.
19. Siegmund, A.; Retz, D.; Xi, N.; Dominguez, C.; Bürli, R.; Liu, L. Selective μ-hydroxyethylation at the N-1 position of a pyrazolone: synthesis of benzyl 1-(μ-hydroxyethyl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H- pyrazole-4-carboxylate. Synlett. 2008, 1005-1008.
20. Lopez, R.; Leon, G.; Oliva, A. 4-Alkoxycarbonyl, 4-alkylthiocarbonyl and 5-alkoxycarbonyloxy derivatives of 1-substituted-3-methylpyrazol-5-ones. J. Heterocycl. Chem. 1995, 32, 1377-1379.
21. Lauer, W. M.; Arnold, R. T.; Tiffany, B.; Tinker, J. Synthesis of some chloromethoxyquinolines. J. Am. Chem. Soc. 1946, 68, 1268-1269.
22. Nelson, S. D. Metabolic activation and drug toxicity. J. Med. Chem. 1982, 25, 753-765.
23. Huang, X.; Buchwald, S. L. Org. Lett. 2001, 3, 3417-3419.
24. Wang, W.; Marimuthu, A.; Tsai, J.; Kumar, A.; Krupka, H. I.; Zhang, C.; Powell, B.; Suzuki, Y.; Nguyen, H.; Tabrizizad, M.; Luu, C.; West, B. L. Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 3563-3568.
25. 50 = 8 nM). RON has also been implicated in human cancers. (a) Danilkovitch-Miagkova, A.; Duh, F. M.; Kuzmin, I.; Angeloni, D.; Liu, S. L.; Miller, A. D.; Lerman, M. I. Hyaluronidase-2 negatively regulates RON receptor tyrosine kinase and mediates transformation of epithelial cells by jaagsiekte sheep retrovirus. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4580-4585.
26. 50, nM): LCK (730), FES (706), BLK (519), Lyn (506), FLT3 (391), BMX (363), FGR (328), Aurora1(280), CFMS (238), CSK (165), PDGF (120), ITK (62).
27. -6 cm/s; Papp(B-A)/Papp(A-B): 0.8.
28. Park, M.; Dean, M.; Cooper, C. S.; Schmidt, M.; O'Brien, S. J.; Blaire, D. G.; Vande Woude, G. F. Mechanism of met oncogene activation. Cell 1986, 45, 895-904.
29. (a) Koochekpour, S.; Jeffers, M.; Rulong, S.; Taylor, G.; Klineberg, E.; Hudson, E. A.; Resau, J. H.; Vande Woude, G. F. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 1997, 57, 5391-5398.
30. (b) Huang, P. H.; Mukasa, A.; Bonavia, R.; Flynn, R. A.: Brewer, Z. E.; Cavenee, W. K.; Furnari, F. B.; White, F. M. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 12867-12872.